Recruiting Essential Tremor Studies in Mountain View
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic ma...
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is character...
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1...
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of v...
About Essential Tremor Clinical Trials in Mountain View
Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.
There are currently 5 essential tremor clinical trials recruiting participants in Mountain View, CA. These studies are seeking a combined 2,885 participants. Research is being sponsored by EyeBiotech Ltd., Hoffmann-La Roche, AbbVie and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Essential Tremor Clinical Trials in Mountain View — FAQ
Are there essential tremor clinical trials in Mountain View?
Yes, there are 5 essential tremor clinical trials currently recruiting in Mountain View, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Mountain View?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Mountain View research site will contact you about next steps.
Are clinical trials in Mountain View free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Mountain View studies also compensate for your time and travel.
What essential tremor treatments are being tested?
The 5 active trials in Mountain View are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.
Data updated March 2, 2026 from ClinicalTrials.gov